ASIA BEAT: An odd reversal of fortune
This article was originally published in Scrip
Executive Summary
There was a time maybe 10 years ago that foreign pharma multinationals faced hurdles developing their operations in Japan due to delays in the regulatory approvals of new drugs and the local clinical trials to support these.